Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomized, double-blind, placebo-controlled phase 2 trial

M. R. Rigby; L. A. DiMeglio; M. S. Rendell; E. I. Felner; J. M. Dostou; S. E. Gitelman; C. M. Patel; K. J. Griffin; E. Tsalikian; P. A. Gottlieb; C. J. Greenbaum; N. A. Sherry; W. V. Moore; R. Monzavi; S. M. Willi; P. Raskin; A. Moran; W. E. Russell; A. Pinckney; L. Keyes-Elstein; M. Howell; S. Aggarwal; N. Lim; D. Phippard; G. T. Nepom; J. McNamara; M. R. Ehlers

doi:10.1089/dia.2015.1510

Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomized, double-blind, placebo-controlled phase 2 trial

M. R. Rigby, L. A. DiMeglio, M. S. Rendell, E. I. Felner, J. M. Dostou, S. E. Gitelman, C. M. Patel, K. J. Griffin, E. Tsalikian, P. A. Gottlieb, C. J. Greenbaum, N. A. Sherry, W. V. Moore, R. Monzavi, S. M. Willi, P. Raskin, A. Moran, W. E. Russell, A. Pinckney, L. Keyes-ElsteinM. Howell, S. Aggarwal, N. Lim, D. Phippard, G. T. Nepom, J. McNamara, M. R. Ehlers

Pediatric Endocrinology

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	S81-S82
Journal	Diabetes Technology and Therapeutics
Volume	17
DOIs	https://doi.org/10.1089/dia.2015.1510
State	Published - Feb 1 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1089/dia.2015.1510

Find It

Find It at U of M Libraries

Cite this

Rigby, M. R., DiMeglio, L. A., Rendell, M. S., Felner, E. I., Dostou, J. M., Gitelman, S. E., Patel, C. M., Griffin, K. J., Tsalikian, E., Gottlieb, P. A., Greenbaum, C. J., Sherry, N. A., Moore, W. V., Monzavi, R., Willi, S. M., Raskin, P., Moran, A., Russell, W. E., Pinckney, A., ... Ehlers, M. R. (2015). Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomized, double-blind, placebo-controlled phase 2 trial. Diabetes Technology and Therapeutics, 17, S81-S82. https://doi.org/10.1089/dia.2015.1510

Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomized, double-blind, placebo-controlled phase 2 trial. / Rigby, M. R.; DiMeglio, L. A.; Rendell, M. S. et al.
In: Diabetes Technology and Therapeutics, Vol. 17, 01.02.2015, p. S81-S82.

Research output: Contribution to journal › Comment/debate › peer-review

Rigby, MR, DiMeglio, LA, Rendell, MS, Felner, EI, Dostou, JM, Gitelman, SE, Patel, CM, Griffin, KJ, Tsalikian, E, Gottlieb, PA, Greenbaum, CJ, Sherry, NA, Moore, WV, Monzavi, R, Willi, SM, Raskin, P, Moran, A, Russell, WE, Pinckney, A, Keyes-Elstein, L, Howell, M, Aggarwal, S, Lim, N, Phippard, D, Nepom, GT, McNamara, J & Ehlers, MR 2015, 'Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomized, double-blind, placebo-controlled phase 2 trial', Diabetes Technology and Therapeutics, vol. 17, pp. S81-S82. https://doi.org/10.1089/dia.2015.1510

@article{a5173d1085b443e89c2d4a463298ef4d,

title = "Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomized, double-blind, placebo-controlled phase 2 trial",

author = "Rigby, {M. R.} and DiMeglio, {L. A.} and Rendell, {M. S.} and Felner, {E. I.} and Dostou, {J. M.} and Gitelman, {S. E.} and Patel, {C. M.} and Griffin, {K. J.} and E. Tsalikian and Gottlieb, {P. A.} and Greenbaum, {C. J.} and Sherry, {N. A.} and Moore, {W. V.} and R. Monzavi and Willi, {S. M.} and P. Raskin and A. Moran and Russell, {W. E.} and A. Pinckney and L. Keyes-Elstein and M. Howell and S. Aggarwal and N. Lim and D. Phippard and Nepom, {G. T.} and J. McNamara and Ehlers, {M. R.}",

year = "2015",

month = feb,

day = "1",

doi = "10.1089/dia.2015.1510",

language = "English (US)",

volume = "17",

pages = "S81--S82",

journal = "Diabetes Technology and Therapeutics",

issn = "1520-9156",

publisher = "Mary Ann Liebert Inc.",

}

TY - JOUR

T1 - Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study)

T2 - 12 month results of a randomized, double-blind, placebo-controlled phase 2 trial

AU - Rigby, M. R.

AU - DiMeglio, L. A.

AU - Rendell, M. S.

AU - Felner, E. I.

AU - Dostou, J. M.

AU - Gitelman, S. E.

AU - Patel, C. M.

AU - Griffin, K. J.

AU - Tsalikian, E.

AU - Gottlieb, P. A.

AU - Greenbaum, C. J.

AU - Sherry, N. A.

AU - Moore, W. V.

AU - Monzavi, R.

AU - Willi, S. M.

AU - Raskin, P.

AU - Moran, A.

AU - Russell, W. E.

AU - Pinckney, A.

AU - Keyes-Elstein, L.

AU - Howell, M.

AU - Aggarwal, S.

AU - Lim, N.

AU - Phippard, D.

AU - Nepom, G. T.

AU - McNamara, J.

AU - Ehlers, M. R.

PY - 2015/2/1

Y1 - 2015/2/1

UR - http://www.scopus.com/inward/record.url?scp=84923112610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923112610&partnerID=8YFLogxK

U2 - 10.1089/dia.2015.1510

DO - 10.1089/dia.2015.1510

M3 - Comment/debate

C2 - 25679434

AN - SCOPUS:84923112610

SN - 1520-9156

VL - 17

SP - S81-S82

JO - Diabetes Technology and Therapeutics

JF - Diabetes Technology and Therapeutics

ER -

Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomized, double-blind, placebo-controlled phase 2 trial

UN SDGs

Publisher link

Find It

Other files and links

Cite this